Prevalence of FLT3, NPM1 and CEBPA Mutations and Correlation to Haematological Parameters in Newly Diagnosed Adult Acute Myeloid Leukaemia Patients in North and Northeast Regions of Peninsular Malaysia

Authors

  • Izaz Ul Haq Universiti Sains Malaysia
  • Mat Jusoh Siti Asmaa Universiti Sains Malaysia
  • Shafini Mohamed Yusoff
  • Azlan Husin Universiti Sains Malaysia
  • Ai Sim Goh Hospital Pulau Pinang
  • Noria Abdul Mutalib Hospital Pulau Pinang
  • Badrul Hisham Yahaya Universiti Sains Malaysia
  • Muhamad Farid Johan Universiti Sains Malaysia http://orcid.org/0000-0001-6344-0220
  • Abdul Rahim Hussein Universiti Sains Malaysia

Keywords:

AML, FLT3, NPM1, CEBPA, mutational analysis

Abstract

Acute myeloid leukaemia (AML) is a clinically heterogeneous haematological cancer with increased incidence in the elderly. Genetic mutations remain important prognostic factors for treatment outcome. Our study determined the prevalence and clinical significance of FLT3, NPM1, and CEBPA mutations of AML in the Northern and East Coast of Peninsular Malaysia. Forty-seven de-novo adult patientswere analysed for 3 common classical mutations in AML; FLT3 (exons 14-15 and 20), NPM1 (exon 12), and CEBPA (exon 1) by polymerase chain reaction (PCR), Conformation Sensitive Gel Electrophoresis (CSGE) and Sanger sequencing. The CSGE analysis revealed the following mutation combinations; NPM1+/FLT3-/CEBPA- (17.0%), NPM1-/FLT3-/CEBPA+ (10.6%), FLT3+/NPM1-/CEBPA-(4.3%), NPM1-/FLT3+/CEBPA+ (4.3%), and NPM1+/FLT3+/CEBPA- (2.1%). c.71666delC, c.71674T>A and c.71683insA mutations were identified in 80%, 60% and 40%, respectively, in addition to FLT3-ITD; while c.28026delA (n=3) and c.27837insCAGA (n=4) in NPM1;c.5699_5700insACCCGC (n=2) and c.5711C>G (n=2) in CEBPA. FLT3-ITD and CEBPA mutations were significantly correlated with higher blast percentage (p=0.045), higher WBC count (p=0.005), and higher platelet count (p=0.001). NPM1-/FLT3+/CEBPA- (1.0%), NPM1-/FLT3-/CEBPA+ (0.8%) and NPM1+/FLT3-/CEBPA- (0.5%) have the longest one-year cumulative overall survival (OS), but not significant (p>0.05). The different types of molecular variants found within the FLT3, NPM1 and CEBPA hotspots, hinting intraclonal diversities which their translocated proteins display distinct features for future prognosis of AML.

References

Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015;373(12):1136-52.

Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.

Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417-23.

Shah A, Andersson TML, Rachet B, Björkholm M, Lambert PC. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population–based study. Br J Haematol. 2013;162(4):509-16.

Yu J, Jiang PYZ, Sun H, Zhang X, Jiang Z, Li Y, et al. Advances in targeted therapy for acute myeloid leukemia. Biomarker Research. 2020;8(1):17.

Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, et al. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. Cancer Discov. 2020;10(4):506-25.

Roloff GW, Odenike O, Bajel A, Wei AH, Foley N, Uy GL. Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022. American Society of Clinical Oncology Educational Book. 2022(42):568-83

Stein EM, Aldoss I, DiPersio JF, Stone RM, Arellano ML, Rosen G, et al. Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101). Blood. 2021;138(Supplement 1):699-702.

Mardiana S, Gill S. CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Front Oncol [Internet]. 2020 2020; 10:[697 p.]. Available from: http://europepmc.org/abstract/MED/32435621

https://doi.org/10.3389/fonc.2020.00697

https://europepmc.org/articles/PMC7218049

https://europepmc.org/articles/PMC7218049?pdf=render.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47.

Fröhling S, Scholl C, Gilliland DG, Levine RL. Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications. J Clin Oncol. 2005;23(26):6285-95.

Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. N Engl J Med. 2008;358(18):1909-18.

Chen S-J, Shen Y, Chen Z. A panoramic view of acute myeloid leukemia. Nat Genet. 2013;45(6):586-7.

Shen Y, Zhu Y-M, Fan X, Shi J-Y, Wang Q-R, Yan X-J, et al. Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood. 2011;118(20):5593-603.

Kim Y, Lee GD, Park J, Yoon JH, Kim HJ, Min WS, et al. Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length. Blood Cancer J. 2015;5(8):e336-e.

Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation. Blood. 2014;124(23):3441-9.

Fischer M, Schnetzke U, Spies-Weisshart B, Walther M, Fleischmann M, Hilgendorf I, et al. Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017;102(4):e129-e31.

Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, et al. NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol. 2019;94(6):E158-E60.

Patel SS, Pinkus GS, Ritterhouse LL, Segal JP, Dal Cin P, Restrepo T, et al. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Am J Hematol. 2019;94(8):921-8.

Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP, 3rd, et al. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018;131(25):2816-25.

Tawana K, Rio-Machin A, Preudhomme C, Fitzgibbon J. Familial CEBPA-mutated acute myeloid leukemia. Semin Hematol. 2017;54(2):87-93.

Schmalbrock LK, Dolnik A, Cocciardi S, Sträng E, Theis F, Jahn N, et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021;137(22):3093-104.

Travaglini S, Angelini DF, Alfonso V, Guerrera G, Lavorgna S, Divona M, et al. Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells. Blood Cancer J. 2020;10(8):85.

Yunus NM, Johan MF, Ali Nagi Al-Jamal H, Husin A, Hussein AR, Hassan R. Characterisation and Clinical Significance of FLT3-ITD and non-ITD in Acute Myeloid Leukaemia Patients in Kelantan, Northeast Peninsular Malaysia. Asian Pac J Cancer Prev. 2015;16(12):4869-72.

Mat Yunus N, Hussein AR, Hassan R, Farid Johan M. Conformational Sensitive Gel Electrophoresis (CSGE) as a method for NPM1 mutational screening in patients with Acute Myeloid Leukaemia. Asian Pac J Trop Dis. 2014;4(3):239.

Döhner K, Schlenk RF, Habdank M, Scholl C, Rücker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106(12):3740-6.

Ganguly A. Conformation-Sensitive Gel Electrophoresis. In: Kwok P-Y, editor. Single Nucleotide Polymorphisms: Methods and Protocols. Totowa, NJ: Springer New York; 2003. p. 47-58.

Williams IJ, Goodeve AC. Conformation-Sensitive Gel Electrophoresis. In: Theophilus BDM, Rapley R, editors. PCR Mutation Detection Protocols. Totowa, NJ: Humana Press; 2002. p. 137-50.

Ni J, Hong J, Long Z, Li Q, Xia R, Zeng Q. Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy. Int J Lab Hematol. 2020:1– 9.

Park SH, Chi H-S, Cho Y-U, Jang S, Park C-J. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk. Leuk Res. 2013;37(11):1488-94.

Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, et al. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients. Ann Hematol. 2012;91(7):1051-63.

Wen X-M, Lin J, Yang J, Yao D-M, Deng Z-Q, Tang C-Y, et al. Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. Int J Clin Exp Pathol. 2014;7(10):6832-40.

Khanal N, Upadhyay Banskota S, Bhatt VR. Novel Treatment Paradigms in Acute Myeloid Leukemia. Clin Pharmacol Ther. 2020;108(3):506-14.

Marcucci G, Haferlach T, Döhner H. Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications. J Clin Oncol. 2011;29(5):475-86.

Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2006;109(3):874-85.

Wang K, Zhou F, Cai X, Chao H, Zhang R, Chen S. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation. Hematology. 2020;25(1):211-8.

Strickland SA, Shaver AC, Byrne M, Daber RD, Ferrell PB, Head DR, et al. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leuk Res. 2018;65:67-73.

Bacher U, Schnittger S, Haferlach T. Molecular genetics in acute myeloid leukemia. Curr Opin Oncol. 2010;22(6):646-55.

Brunet S, Labopin M, Esteve J, Cornelissen J, Socié G, Iori AP, et al. Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis. J Clin Oncol. 2012;30(7):735-41.

El Gammal MM, Ebid GT, Madney YM, Abo-Elazm OM, Kelany AK, Torra OS, et al. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients. Clin Lymphoma Myeloma Leuk. 2019;19(6):e281-e90.

Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, et al. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J. 2020;10(5):48.

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016;374(23):2209-21.

Kunchala P, Kuravi S, Jensen R, McGuirk J, Balusu R. When the good go bad: Mutant NPM1 in acute myeloid leukemia. Blood Rev. 2018;32(3):167-83.

Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2006;109(2):431-48.

Saultz JN, Garzon R. Acute Myeloid Leukemia: A Concise Review. J Clin Med. 2016;5(3):33.

Roloff GW, Griffiths EA. When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. Blood Adv. 2018;2(21):3070-80.

Snaddon J, Smith ML, Neat M, Cambal-Parrales M, Dixon-McIver A, Arch R, et al. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosom Cancer. 2003;37(1):72-8.

Preudhomme C, Sagot C, Boissel N, Cayuela J-M, Tigaud I, de Botton Sp, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100(8):2717-23.

Mueller BU, Pabst T. C/EBPα and the pathophysiology of acute myeloid leukemia. Curr Opin Hematol. 2006;13(1):7-14.

Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, et al. CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations. J Clin Oncol. 2004;22(4):624-33.

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, et al. Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome. J Clin Oncol. 2010;28(4):570-7.

Nerlov C. C/EBPα mutations in acute myeloid leukaemias. Nat Rev Cancer. 2004;4(5):394-400.

Su L, Gao SJ, Li W, Tan YH, Cui JW, Hu RP. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia. Hematology. 2014;19(6):324-8.

Schneider F, Hoster E, Schneider S, Dufour A, Benthaus T, Kakadia PM, et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol. 2012;91(1):9-18.

Konstandin NP, Pastore F, Herold T, Dufour A, Rothenberg-Thurley M, Hinrichsen T, et al. Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA. Blood Adv. 2018;2(20):2724-31.

Downloads

Published

2023-02-27

Issue

Vol. 8 No. 1 (2023): JUNE 2023

Section

Journal of Biomedical and Clinical Sciences

License

JBCS Publication Ethics

JBCS is committed to ensure the publication process follows specific academic ethics. Hence, Authors, Reviewers and Editors are required to conform to standards of ethical guidelines.

Authors
Authors should discuss objectively the significance of research work, technical detail and relevant references to enable others to replicate the experiments. JBCS do not accept fraudulent or inaccurate statements that may constitute towards unethical conduct.

Authors should ensure the originality of their works. In cases where the work and/or words of others have been used, appropriate acknowledgements should be made. JBCS do not accept plagiarism in all forms that constitute towards unethical publishing of an article.

This includes simultaneous submission of the same manuscript to more than one journal. Corresponding author is responsible for the full consensus of all co-authors in approving the final version of the paper and its submission for publication.

Reviewers
Reviewers of JBCS treat manuscripts received for review as confidential documents. Therefore, Reviewers must ensure the confidentiality and should not use privileged information and/or ideas obtained through peer review for personal advantage.

Reviews should be conducted based on academic merit and observations should be formulated clearly with supporting arguments. In cases where selected Reviewer feels unqualified to review a manuscript, Reviewer should notify the editor and excuse himself from the review process in TWO (2) weeks time from the review offer is made.

In any reasonable circumstances, Reviewers should not consider to evaluate manuscripts if they have conflicts of interest (i.e: competitive, collaborative and/or other connections with any of the authors, companies, or institutions affiliated to the papers).

Editors
Editors should evaluate manuscripts exclusively based on their academic merit. JBCS strictly do not allow editors to use unpublished information of authors  without the written consent of the author. Editors are required to take appropriate responsive actions if ethical complaints have been presented concerning a submitted manuscript or published paper.

CONFLICT OF INTEREST

Journal of Biomedical and Clinical Sciences requires authors to declare all competing interests in relation to their work. All submitted manuscripts must include a ‘competing interests section at the end of the manuscript listing all competing interests (financial and non-financial). Where authors have no competing interests, the statement should read ,The authors have declared that no competing interests exist. Editors may ask for further information relating to competing interests.

Editors and reviewers are also required to declare any competing interests and will be excluded from the peer review process if a competing interest exists. Competing interests may be financial or non-financial. A competing interest exists when the authors interpretation of data or presentation of information may be influenced by their personal or financial relationship with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the article.

HUMAN AND ANIMAL RIGHTS

All research must have been carried out within an appropriate ethical framework. If there is suspicion that work has not taken place within an appropriate ethical framework, Editors will follow the Misconduct policy and may reject the manuscript, and/or contact the author(s) institution or ethics committee. On rare occasions, if the Editor has serious concerns about the ethics of a study, the manuscript may be rejected on ethical grounds, even if approval from an ethics committee has been obtained.

Research involving human subjects, human material, or human data, must have been performed in accordance with the Declaration of Helsinki and must have been approved by an appropriate ethics committee. A statement detailing this, including the name of the ethics committee and the reference number where appropriate, must appear in all manuscripts reporting such research. Further information and documentation to support this should be made available to Editors on request.

Experimental research on vertebrates or any regulated invertebrates must comply with institutional, national, or international guidelines, and where available should have been approved by an appropriate ethics committee. The Basel Declaration outlines fundamental principles to adhere to when conducting research in animals and the International Council for Laboratory Animal Science (ICLAS) has also published ethical guidelines.

A statement detailing compliance with relevant guidelines (e.g. the revised Animals (Scientific Procedures) Act 1986 in the UK and Directive 2010/63/EU in Europe) and/or ethical approval (including the name of the ethics committee and the reference number where appropriate) must be included in the manuscript. The Editor will take account of animal welfare issues and reserves the right to reject a manuscript, especially if the research involves protocols that are inconsistent with commonly accepted norms of animal research. In rare cases, Editors may contact the ethics committee for further information.

INFORMED CONSENT

For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the manuscript, this includes to all manuscripts that include details, images, or videos relating to individual participants.

DATA SHARING POLICY

JBCS strongly encourages that all datasets on which the conclusions of the paper rely should be available to readers. We encourage authors to ensure that their datasets are either deposited in publicly available repositories (where available and appropriate) or presented in the main manuscript or additional supporting files, in machine-readable format (such as spreadsheets rather than PDFs) whenever possible

Authors who do not wish to share their data must state that data will not be shared, and give the reason.

COPYRIGHT NOTICE

The JBCS retains the copyright of published manuscripts under the terms of the Copyright Transfer Agreement. However, the journal permits unrestricted use, distribution, and reproduction in any medium, provided permission to reuse, distribute and reproduce is obtained from the Journal's Editor and the original work is properly cited.

While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Copyright (c) 2023 Journal of Biomedical and Clinical Sciences (JBCS)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.